Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-553P (RNA, U6 small nuclear 553, pseudogene) is classified as a pseudogene of the U6 small nuclear RNA (snRNA) family[4]. While the canonical U6 snRNA is an essential RNA component of the spliceosome that catalyzes pre-mRNA splicing in eukaryotic cells[1][3], pseudogenes such as RNU6-553P do not produce a functional RNA product and are generally considered non-functional remnants of gene duplication or retrotransposition events[4]. There is no evidence that RNU6-553P serves as a protein, enzyme, receptor, transporter, or other functional molecular target. As such, it is not considered a therapeutic target or involved directly in biological pathways, nor is there literature supporting a role in disease, pharmacology, or clinical biomarker use[4][2]. There can be confusion because the U6 snRNA gene family contains many functional and nonfunctional (pseudogene) copies in the human genome[5]. To summarize, RNU6-553P is a pseudogene corresponding to a small nuclear RNA, with no current evidence of transcriptional, biological, or pharmacological function, and is not considered a therapeutic target[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 553, pseudogene (RNU6-553P).